Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Adaptive Biotechnologies Corp Stock Research

ADPT

5.18USD-0.25(-4.60%)Market Closed
Watchlist

Market Summary

USD5.18-0.25
Market Closed
-4.60%

ADPT Alerts

  • Losses in recent quarter

ADPT Stock Price

ADPT RSI Chart

ADPT Valuation

Market Cap

749.3M

Price/Earnings (Trailing)

-3.92

Price/Sales (Trailing)

3.95

Price/Free Cashflow

-4.41

ADPT Price/Sales (Trailing)

ADPT Profitability

Return on Equity

-46.02%

Return on Assets

-24.66%

Free Cashflow Yield

-22.65%

ADPT Fundamentals

ADPT Revenue

Revenue (TTM)

189.6M

Revenue Y/Y

12.06%

Revenue Q/Q

29.96%

ADPT Earnings

Earnings (TTM)

-190.9M

Earnings Y/Y

8.14%

Earnings Q/Q

17.14%

Price Action

52 Week Range

5.1010.79
(Low)(High)

Last 7 days

-21.0%

Last 30 days

-19.6%

Last 90 days

-28.2%

Trailing 12 Months

-31.6%

ADPT Financial Health

Current Ratio

5.56

ADPT Investor Care

Shares Dilution (1Y)

1.60%

Diluted EPS (TTM)

-1.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for ADPT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-08
SOOD NITIN
sold
-68,997
6.54
-10,550
chief commercial officer, mrd
2023-08-07
SOOD NITIN
sold
-38,320
6.78
-5,652
chief commercial officer, mrd
2023-06-20
PETERSON TYCHO
acquired
985,215
7.3
134,961
chief financial officer
2023-06-20
PETERSON TYCHO
sold
-1,098,580
8.14
-134,961
chief financial officer
2023-06-15
PETERSON TYCHO
acquired
104,594
7.3
14,328
chief financial officer
2023-06-15
PETERSON TYCHO
sold
-597,100
8.53
-70,000
chief financial officer
2023-06-02
PETERSON TYCHO
sold
-272,080
7.16
-38,000
chief financial officer
2023-04-11
ADAMS R MARK
sold
-19,918
8.63
-2,308
chief operating officer
2023-04-10
ADAMS R MARK
sold
-6,944
8.5
-817
chief operating officer
2023-03-27
GRIFFIN MICHELLE RENEE
sold
-19,878
8.4913
-2,341
-

1–10 of 50

Which funds bought or sold ADPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
-108
342
-%
2023-09-07
Triatomic Management LP
added
58.26
136,999
813,024
0.83%
2023-08-23
Rappaport Reiches Capital Management, LLC
unchanged
-
-144,329
456,817
0.19%
2023-08-22
Asset Dedication, LLC
added
5.44
-3,000
8,000
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
unchanged
-
-43,248
136,884
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-64.56
-333,907
123,052
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-2.63
-297,174
845,393
-%
2023-08-18
Legato Capital Management LLC
added
39.55
38,287
671,248
0.09%
2023-08-16
Nuveen Asset Management, LLC
reduced
-39.11
-5,817,430
5,009,570
-%
2023-08-15
CAPTRUST FINANCIAL ADVISORS
added
0.57
-25,245
81,828
-%

1–10 of 47

Latest Funds Activity

Are funds buying ADPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADPT
No. of Funds

Schedule 13G FIlings of Adaptive BioTech

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
blackrock inc.
8.7%
12,374,197
SC 13G
Feb 09, 2023
vanguard group inc
8.25%
11,794,168
SC 13G/A
Sep 12, 2022
price t rowe associates inc /md/
2.9%
4,081,518
SC 13G/A
Feb 14, 2022
viking global investors lp
21.3%
29,993,708
SC 13G/A
Feb 14, 2022
matrix capital management company, lp
8.20%
11,572,590
SC 13G/A
Feb 10, 2022
price t rowe associates inc /md/
9.4%
13,286,713
SC 13G
Feb 10, 2022
price t rowe associates inc /md/
10.0%
14,240,614
SC 13G/A
Feb 09, 2022
vanguard group inc
7.82%
11,031,288
SC 13G/A
Feb 16, 2021
matrix capital management company, lp
9.59%
13,115,090
SC 13G/A
Feb 16, 2021
viking global investors lp
21.9%
29,993,708
SC 13G/A

Recent SEC filings of Adaptive BioTech

View All Filings
Date Filed Form Type Document
Sep 01, 2023
8-K
Current Report
Aug 08, 2023
4
Insider Trading
Aug 08, 2023
144
Notice of Insider Sale Intent
Aug 02, 2023
8-K
Current Report
Aug 02, 2023
10-Q
Quarterly Report
Jul 03, 2023
8-K
Current Report
Jun 21, 2023
4
Insider Trading
Jun 20, 2023
4
Insider Trading
Jun 20, 2023
144
Notice of Insider Sale Intent
Jun 15, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Adaptive BioTech)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.0B
7.0B
-5.38% -12.23%
29.09
4.71
5.03% -14.68%
24.7B
4.0B
-3.30% -3.12%
27.83
6.25
2.30% 16.37%
21.9B
4.5B
-17.36% -28.94%
-5.22
4.9
-4.92% -21931.58%
11.2B
1.1B
-9.93% -5.35%
39.16
9.83
2.81% 4.86%
MID-CAP
9.4B
134.2M
4.73% -21.54%
68.08
70.03
-82.77% -13.43%
SMALL-CAP
2.4B
146.1M
-8.89% 61.75%
-7.4
16.16
4.72% -55.19%
960.9M
112.0M
5.18% 169.83%
-14.6
8.58
0.83% 16.42%
749.3M
189.6M
-19.57% -31.57%
-3.92
3.95
18.74% 17.75%
175.0M
114.1M
-1.44% 44.37%
-32.24
1.53
-5.49% -48.58%
118.7M
99.2M
-1.73% -74.89%
-2.09
1.2
-26.56% -199.52%
103.3M
80.9M
-10.97% -2.13%
-15.91
1.28
17.20% 77.07%
99.7M
31.5M
-1.32% 40.85%
-0.68
3.16
35.12% -38.47%
73.7M
143.9M
-41.73% -89.43%
-0.44
0.51
0.71% -18.99%
72.1M
52.7M
-20.39% -41.08%
-9.55
1.37
2.10% -1984.29%

Adaptive BioTech News

Scenari Economici
Le 1001 azioni che si sono schiantate sul mercato azionario USA.
Scenari Economici,
11 months ago
Nasdaq

Returns for ADPT

Cumulative Returns on ADPT

-51.8%


3-Year Cumulative Returns

Risks for ADPT

What is the probability of a big loss on ADPT?

98.7%


Probability that Adaptive BioTech stock will be more than 20% underwater in next one year

93.3%


Probability that Adaptive BioTech stock will be more than 30% underwater in next one year.

90.1%


Probability that Adaptive BioTech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ADPT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Adaptive BioTech was unfortunately bought at previous high price.

Drawdowns

Financials for Adaptive BioTech

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.9%189,601,000184,335,000185,308,000168,040,000159,677,000154,522,000154,344,000146,599,000133,431,000115,914,00098,382,00092,406,00092,165,00093,315,00085,071,00078,054,00069,184,00058,614,00055,663,00057,512,00046,272,000
  S&GA Expenses-0.4%91,409,00091,818,00095,603,00098,583,000102,019,000100,954,00095,465,00087,314,00076,839,00067,955,00061,358,00055,453,00050,078,00044,643,00038,453,00033,884,00030,824,00027,256,00024,486,00022,736,00021,316,000
  R&D Expenses-3.5%131,718,000136,518,000141,756,000145,233,000145,647,000146,410,000142,343,000143,475,000137,717,000125,909,000116,072,000101,430,00091,622,00082,157,00070,705,00060,583,00049,860,00042,785,00039,157,00038,470,00037,808,000
EBITDA------190,369,000-192,659,000-195,044,000---123,907,000-123,907,000-46,286,000-46,286,000-46,286,000-46,286,000------
EBITDA Margin------1.19-1.25-1.26---1.07-1.26-0.50-0.50-0.50-0.54------
Interest Expenses9.8%11,374,00010,358,6674,238,0002,612,000-----------------
EBT Margin------1.30-1.34-1.34---1.26-1.49-0.74-0.74-0.74-0.81------
Net Income2.2%-190,918,000-195,154,000-200,191,000-221,496,000-232,118,000-236,070,000-207,279,000-197,113,000-177,929,000-155,466,000-146,227,000-122,268,000-99,499,000-81,623,000-68,606,000-61,266,000-55,608,000-52,442,000-46,447,000-41,570,000-49,972,000
Net Income Margin100.0%--1.06-1.08-1.32-1.45-1.48-1.34-1.30-1.28-1.34-1.49-1.32-1.08-0.87-0.81------
Free Cashflow100.0%--194,840,000-200,294,000-230,804,000-241,026,000-247,917,000-254,473,000-240,616,000-233,917,000-208,003,000-168,486,000-148,479,000-130,684,000-114,837,000194,204,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q42017Q4
Assets-3.4%7657918578848078589239931,0331,0721,1161,095855875912917601333362
  Current Assets-4.9%477501562564439419403467644765727877600585613601442181205
    Cash Equivalents15.5%10995.0090.0021876.0011513912218417412349736521397.0075.0048.0055.0085.00
  Inventory-4.6%19.0020.0014.0017.0019.0021.0019.0018.0019.0017.0014.0011.0011.0011.009.009.008.008.005.00
  Net PPE-2.3%79.0081.0083.0087.0087.0086.0085.0088.0075.0056.0040.0031.0027.0025.0060.0047.0022.0019.0014.00
  Goodwill0%119119119119119119119119119119119119119119119119119119119
Liabilities0.3%36936839339628830531934134034637332032532334133132430.0026.00
  Current Liabilities5.8%95.0090.0011010411111511412211710710510193.0078.0078.0073.0075.0023.0021.00
Shareholder's Equity-6.6%396424464488518553604652693726743775530552571586---
  Retained Earnings-4.9%-1,024-976-919-878-833-781-718-657-601-552-511-467-430-396-365-344-330-295-249
  Additional Paid-In Capital1.3%1,4221,4031,3871,3731,3581,3401,3241,3091,2951,2771,2541,24195894593693046.0038.0025.00
Shares Outstanding0.3%14514414314314214214114114013913812912712669.0051.0013.0013.0012.00
Minority Interest-1.5%-0.07-0.07-0.07-0.030.000.000.000.000.000.00---------
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations13.2%-155,135-178,644-183,945-207,752-208,787-198,935-192,727-178,745-182,458-176,322-149,683-136,630-119,612-104,505205,404226,785245,237348,276-32,259-46,744-30,326
  Share Based Compensation5.5%60,45257,28755,47753,05850,55947,62843,25138,61933,44628,57024,76120,92917,75914,71813,12412,72411,97711,04511,1499,9069,600
Cashflow From Investing115.5%60,77328,1962,905167,66188,378125,079181,210-226,051-302,029-165,984-117,044269,685106,079-116,762-481,697-500,748-234,763-252,55273620,532-64,052
Cashflow From Financing-1.9%127,667130,188132,265135,53712,94315,28127,14630,121303,233303,242293,587289,080332,592324,751319,916318,448-1,0456121,2482281,826

ADPT Income Statement

2023-06-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ 48,926$ 43,660$ 86,573$ 82,280
Operating expenses    
Cost of revenue17,91013,22136,59126,413
Research and development32,23737,03764,83874,876
Sales and marketing23,87224,28146,18050,374
General and administrative22,30221,20043,13345,344
Amortization of intangible assets423423842842
Total operating expenses96,74496,162191,584197,849
Loss from operations(47,818)(52,502)(105,011)(115,569)
Interest and other income, net3,6124186,636689
Interest expense(3,605) (7,136) 
Net loss(47,811)(52,084)(105,511)(114,880)
Add: Net loss attributable to noncontrolling interest138298
Net loss attributable to Adaptive Biotechnologies Corporation$ (47,810)$ (52,046)$ (105,509)$ (114,782)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic$ (0.33)$ (0.37)$ (0.73)$ (0.81)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic144,397,693142,363,589143,956,867142,032,261
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted$ (0.33)$ (0.37)$ (0.73)$ (0.81)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted144,397,693142,363,589143,956,867142,032,261

ADPT Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 109,240$ 90,030
Short-term marketable securities (amortized cost of $308,885 and $412,282, respectively)307,990408,166
Accounts receivable, net31,54540,057
Inventory18,96014,453
Prepaid expenses and other current assets9,0749,440
Total current assets476,809562,146
Long-term assets  
Property and equipment, net79,39083,447
Operating lease right-of-use assets77,10980,763
Restricted cash2,9232,398
Intangible assets, net5,9856,827
Goodwill118,972118,972
Other assets3,3522,064
Total assets764,540856,617
Current liabilities  
Accounts payable9,1638,084
Accrued liabilities8,35612,424
Accrued compensation and benefits10,55415,935
Current portion of operating lease liabilities9,3459,230
Current portion of deferred revenue57,91764,115
Total current liabilities95,335109,788
Long-term liabilities  
Operating lease liabilities, less current portion94,17698,772
Deferred revenue, less current portion50,89558,599
Revenue interest liability, net128,167125,360
Total liabilities368,573392,519
Commitments and contingencies (Note 9)
Shareholders’ equity  
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2023 and December 31, 2022; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2023 and December 31, 2022; 144,645,118 and 143,105,002 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively1414
Additional paid-in capital1,421,5061,387,349
Accumulated other comprehensive loss(893)(4,116)
Accumulated deficit(1,024,591)(919,082)
Total Adaptive Biotechnologies Corporation shareholders’ equity396,036464,165
Noncontrolling interest(69)(67)
Total shareholders’ equity395,967464,098
Total liabilities and shareholders’ equity$ 764,540$ 856,617
Chad Robins
860
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.